Payer News
May 2020

ASCO Published Recommendations on Germline and Somatic Testing of Ovarian Cancer

A new, evidence-based guideline released by the American Society of Clinical Oncology (ASCO) for testing women with ovarian cancer

  • All women with ovarian cancer be tested with a multigene panel that includes at least these 10 genes
    • BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, MLH1, MSH2, MSH6, PMS2, and PALB2
  • Epithelial ovarian cancer patients with negative germline BRCA results should be offered BRCA somatic (tumor) testing
  • Nongenetic providers familiar with hereditary cancer testing can provide pretest counseling and facilitate genetic testing for epithelial ovarian cancer patients

You can find the complete publication here

Myriad's myRisk Hereditary Cancer panel test was designed as a replacement for BRCA1/2 testing and satisfies the requirements of this new guideline. 

Learn more about myRisk


Myriad, the Myriad logo, Myriad myRisk Hereditary Cancer and the Myriad myRisk Hereditary Cancer logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions, ©2020 Myriad Genetic Laboratories, Inc. 


Myriad Genetic Laboratories, Inc. 320 Wakara Way Salt Lake City UT 84108 United States

You received this email because you are subscribed to Marketing Information from Myriad Genetic Laboratories, Inc..
Update your email preferences or unsubscribe.